ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah

Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick.